Sort
141,003 grants matching “cytokine”
Safe and Efficacious Oral MIF Inhibitors for Rheumatoid Arthritis
$995,900Anderson Gaweco · Innovimmune Biotherapeutics Holding, Llc · R44 · FY2016 · AI
Safe and Efficacious Oral MIF Inhibitors for Rheumatoid Arthritis
$995,900Anderson Gaweco · Innovimmune Biotherapeutics Holding, Llc · R44 · FY2015 · AI
Safe and Efficacious Oral MIF Inhibitors for Rheumatoid Arthritis
$995,900Anderson Gaweco · Innovimmune Biotherapeutics Holding, Llc · R44 · FY2014 · AI
Opiate drug abuse and CNS vulnerability to HIV
$995,804Kurt Francis Hauser · Virginia Commonwealth University · P01 · FY2008 · DA
Targeting leukocyte metabolism to treat human autoimmune disease
$995,802Jay L Rothstein · Immunext, Inc. · R44 · FY2020 · AI
Targeting leukocyte metabolism to treat human autoimmune disease
$995,802Jay L Rothstein · Immunext, Inc. · R44 · FY2018 · AI
Reprogramming of T cells for the Treatment of Melanoma
$995,664Kai W Wucherpfennig · Dana-Farber Cancer Inst · R01 · FY2014 · CA
Reprogramming of T cells for the Treatment of Melanoma
$995,664Kai W Wucherpfennig · Dana-Farber Cancer Inst · R01 · FY2016 · CA
Reprogramming of T cells for the Treatment of Melanoma
$995,664Kai W Wucherpfennig · Dana-Farber Cancer Inst · R01 · FY2015 · CA
Abdominal Symptom Phenotypes: Pathways to New Biomarkers
$995,519Margaret McLean Heitkemper · University Of Washington · RC2 · FY2009 · NR
Deciphering Biological Linkages Between PTSD and Respiratory Disease in WTC Respo
$995,508Benjamin J Luft · State University New York Stony Brook · U01 · FY2015 · OH
ErythroMer: Nanoscale BioSynthetic Red Cell Substitute
$995,470Esma Alp · Kalocyte, Inc. · R44 · FY2025 · HL
Patterning of Transcription Factor Activity in T cells During Influenza Infection
$995,168Rajat Varma · National Institute Of Allergy And Infectious Diseases · ZIA · FY2010 · AI
Development of VNLG-152R as novel therapeutic for triple negative breast cancer
$995,100Vidya P Ramamurthy · Isoprene Pharmaceuticals, Inc. · R44 · FY2021 · CA
Development of VNLG-152R as novel therapeutic for triple negative breast cancer
$995,100Vidya P Ramamurthy · Isoprene Pharmaceuticals, Inc. · R44 · FY2022 · CA
Tumor Immune Contexture and Breast Cancer Disparities: A Multi-Disciplinary Study in Women of African and European Ancestry
$994,901Christine B. Ambrosone · Roswell Park Cancer Institute Corp · R01 · FY2020 · CA
Boosting Innate Immunity Through HIF to Treat Antibiotic-Resistant Infections
$994,866Victor Nizet · University Of California, San Diego · R01 · FY2012 · AI
CTO1681 to prevent and mitigate cytokine release syndrome in CAR T-cell recipients
$994,859Arthur P Bertolino · Cytoagents, Inc. · R44 · FY2024 · CA
Opiate drug abuse and CNS vulnerability to HIV
$994,858Kurt Francis Hauser · Virginia Commonwealth University · P01 · FY2007 · DA
INNATE AND ADAPTIVE MICROBIAL IMMUNITY IN IBD
$994,852Charles O Elson · University Of Alabama At Birmingham · P01 · FY2008 · DK
3D Bioprinted skin models for drug screening
$994,550Marc Ferrer · National Center For Advancing Translational Sciences · ZIA · FY2024 · TR
A Single-cell Platform for Analyzing the Peripheral Immune Response in Alzheimerâs and Alzheimerâs Related Diseases
$994,372Timothy S McConnell · Isoplexis, Inc. · R44 · FY2021 · AG
Project 4: Longitudinal Brain Imaging for Alzheimer's Biomarkers across Peri to Post Menopausal Transition: Therapeutic Targets and Windows
$994,350Lisa Mosconi · University Of Arizona · P01 · FY2025 · AG
Human Retinal Pigment Epithelial Physiology
$994,295Sheldon Miller · National Eye Institute · ZIA · FY2015 · EY
Sociodemographic Disparities in SLE Incidence: Behavioral and Psychosocial Factors
$994,269Karen H Costenbader · Brigham And Women'S Hospital · R01 · FY2017 · AR